Abstract
As cholinergic mechanisms may be at least partially responsible for hallucinations and delusions in Parkinson’s disease (PD), we conducted an open study in 8 PD patients to assess the efficacy and tolerability of the cholinesterase inhibitor donepezil, 5 mg at bedtime for two months, in the treatment of these complications. Hallucinations and delusions improved significantly in all patients. Donezepil was overall well tolerated, but a deterioration in motor disability was noted in 2 out of 8 patients.
Author information
Authors and Affiliations
Additional information
Received: 21 september 2001 / Accepted in revised form: 6 February 2002
Rights and permissions
About this article
Cite this article
Fabbrini, G., Barbanti, P., Aurilia, C. et al. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol Sci 23, 41–43 (2002). https://doi.org/10.1007/s100720200022
Published:
Issue Date:
DOI: https://doi.org/10.1007/s100720200022